Navigation Links
Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals to Settle Patent Litigation Over Rythmol(R) SR
Date:4/21/2009

WOODCLIFF LAKE, N.J., April 21 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) ("Par") today announced it has entered into a settlement agreement with Reliant Pharmaceuticals, Inc. ("Reliant") that resolves patent litigation related to Reliant's Rythmol(R) SR product, thereby eliminating the inherent uncertainty and costs of litigation.

Under the terms of the settlement, Par will have the right to introduce a generic version of Rythmol(R) SR on January 1, 2011, or earlier under certain circumstances. Propafenone extended release capsules are indicated to prolong the time to recurrence of symptomatic atrial fibrillation in patients without structural heart disease. The use of Propafenone ER capsules in patients with permanent atrial fibrillation or in patients exclusively with atrial flutter or PSVT has not been evaluated. Propafenone ER capsules should not be used to control ventricular rate during atrial fibrillation. The effect of Propafenone ER capsules on mortality has not been determined. Rythmol(R) SR had combined U.S. sales of approximately $119 million for the twelve months ended September 2008, according to IMS Health.

In accordance with the settlement agreement, all ongoing patent litigation between Reliant Pharmaceuticals and Par Pharmaceutical, Inc., in the U.S. District Court for the District of Delaware, has been dismissed.

About Par

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constit
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... 17, 2009 Racial and ethnic disparities in ... be detected early and treated successfully, including breast ... researchers at Columbia University,s Mailman School of Public ... at Columbia University Medical Center/NewYork-Presbyterian Hospital. Disparities ... more limited early detection and treatment options, such ...
(Date:12/17/2009)... someday ease accompanying lung infections , , THURSDAY, Dec. 17 ... infected with the swine flu virus, and researchers say ... key to the severity of the illness appears to ... the immune system fight off germs and disease. Researchers ... at 10 Spanish hospitals last summer found the highest ...
(Date:12/17/2009)... Program rewards eligible physicians meeting quality standards. Open to primary ... qualify for double-digit increases in reimbursement for commonly billed services, ... ... December 16, 2009 -- Blue Cross and Blue Shield ... reward health care quality in North Carolina by introducing a ...
(Date:12/17/2009)... Smith recently hired Deirdre Byrne to lead the firm’s Interim Leadership ... years of experience in healthcare consulting, Byrne will assume her duties ... ... (Vocus) December 17, 2009 -- B. E. Smith recently ... senior vice president. A seasoned executive with nearly 20 years of ...
(Date:12/17/2009)... Motionsoft, Inc. announced today that it has been ... Security Standards (DSS) certification, making it one of ... health and wellness space that has been granted ... result of a collaborative effort formed by the ... Worldwide, American Express, Discover Financial Services and JCB) ...
Breaking Medicine News(10 mins):Health News:Cancer survival disparities for most minority populations increase as cancers become more treatable 2Health News:BCBSNC Rewarding Physicians for Better Care, Not More Care, Through Blue Quality Physician Program, 2Health News:BCBSNC Rewarding Physicians for Better Care, Not More Care, Through Blue Quality Physician Program, 3Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3Health News:Motionsoft Completes PCI Compliance Certification 2
... juice with added vitamin A has the ability to reduce ... studies as// evidence. ,In the first study involving ... levels of chemical markers in the blood samples of people ... linked to a lower risk of liver disease, arteriosclerosis and ...
... was so fearful over his daughter Nicole's drastic weight loss that ... out the problem.// ,According to contactmusic.com, Richie was scared ... an eating disorder. ,He says: "Believe me, I've ... I went to her, and I said, 'Okay, what is it?' ...
... left the comforts of home to live in a dorm ... dad may be great, but dorm-life// also has its downfalls, ... picked up in communal bathrooms/showers. “Shared showers are one of ... wet, steamy atmosphere is a great place for them to ...
... cranberry juice have the ability to change E. coli ... of human illnesses, in ways that render them unable ... scientists at the Worcester Polytechnic Institute (WPI), Massachusetts, suggests ... E. coli bacteria that have become resistant to conventional ...
... over $100,000 from drug companies in unauthorized deals with the ... newspaper on Sunday. ,The actions of Dr. Thomas J. ... review, which concluded that he was guilty of "serious misconduct" ... the Los Angeles Times. ,The review found, "Dr. Walsh ...
People who have a low response to alcohol or the so called ability to...
Other Medicine News:Health News:Tips for Avoiding Foot Fungus in Communal Bathrooms 2Health News:Medical researcher Accused of 'serious misconduct' 2
(Date:12/16/2009)... 16 Today, a group of national medical ... H.R. 3590, the Patient Protection and Affordable Care Act, ... its way towards a final vote in the coming ... Senators to vote against a health care bill that ... first hand that our health care system needs reform ...
(Date:12/16/2009)... WORTH, Texas, Dec. 16 Wound ... a rapidly growing provider of specialty medical ... operating subsidiary is moving toward productization of ... The company currently anticipates products to be ... market, estimated to be a multi-billion dollar ...
(Date:12/16/2009)... HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) an online U.S. ... in 12% per annum short term debt financing. ... drawdown of $500,000, with accrued interest and principal repayable ... accrued interest and principal repayable in one year from ... positive for any calendar month prior to December 15, ...
Breaking Medicine Technology:Physician Groups Oppose Current Senate Health Care Reform Bill 2Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 2Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 3HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2Recondo Technology Introduces New Software Service for Hospitals 53761 1Recondo Technology Introduces New Software Service for Hospitals 53761 2ADVENTRX Pharmaceuticals Announces Financing 13392 1ADVENTRX Pharmaceuticals Announces Financing 13392 2ADVENTRX Pharmaceuticals Announces Financing 13392 3ADVENTRX Pharmaceuticals Announces Financing 13392 4MaxLife Fund Corp announces cancellation of 14 050 000 Common Shares 53754 1MaxLife Fund Corp announces cancellation of 14 050 000 Common Shares 53754 2
... Suppresses Amyloid Plaque Formation, ANNAPOLIS, Md., April ... biodefense company specializing in the development,and commercialization ... announced today that new data from its,recombinant ... the 8th International Conference on,Alzheimer's and Parkinson's ...
... Vitro Assays Show rBChE Suppresses Amyloid Plaque,Formation ... PharmAthene, Inc., a leading,biodefense company specializing in ... chemical and,biological terrorism, announced today that new ... were,recently presented at the 8th International Conference ...
Other Medicine Technology:PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: